Navigation Links
Daktari Accepted into WHO Prequalification of Diagnostics Programme
Date:7/18/2014

CAMBRIDGE, Mass., July 18, 2014 /PRNewswire/ -- Daktari Diagnostics is pleased to announce the acceptance of the Daktari CD4 Instrument into the Prequalification of Diagnostics Programme within the World Health Organization (WHO). The Daktari CD4 is a portable and wirelessly connected point-of-care diagnostic platform that can deliver a patient's CD4 cell count in less than 15 minutes, all from a single drop of blood.

The Daktari CD4 is geared toward resource-limited settings and is the first of Daktari's point-of-care technologies to enter the commercialization phase.

Facilitated through the Diagnostics and Laboratory Technology Team (DLT) within the department of Essential Health Technologies (EHT), the goal of the WHO Prequalification of Diagnostics program is to encourage and simplify access to safe, inexpensive, and high quality diagnostic devices intended to address the most pressing global diseases. As part of the WHO Prequalification of Diagnostics Programme, the Daktari CD4 will undergo extensive and thorough evaluation in hopes of receiving prequalification status of diagnostics. If approved, the Daktari CD4 will be eligible for procurement in United Nations' tenders.

"We are thrilled that the Daktari CD4 has been accepted into the WHO Prequalification of Diagnostics Programme," said Betsy Wonderly, Daktari's Global Product Manager. "Our team has been working incredibly hard day in and day out to bring the Daktari CD4 to those who need it the most, and being a part of the Prequalification of Diagnostics Programme is a big step forward in achieving that goal."

About WHO

WHO is the primary authority for health as part of the United Nations, where its main focus is to offer guidance and direction on global health issues by developing the health research agenda, declaring global health benchmarks, communicating policy options, delivering support to countries and keeping up with global health trends. WHO is governed by The World Health Assembly, which is made up of representatives from 194 Member States. The World Health Assembly meets once each year in Geneva to discuss and solidify guidelines.

About Daktari

Daktari Diagnostics, Inc. (www.daktaridx.com) is a venture-backed company based in Cambridge, USA. Daktari's corporate mission is to address the world's biggest health problems by building a market-leading business around a fleet of accurate, portable diagnostic products that can be deployed anywhere in the world. The Daktari technology platform combines electrochemical sensing with microfluidics, enabling highly accurate, low-cost diagnostics in a handheld format. The Daktari connectivity platform provides seamless data management for results produced at any health facility.

Media Contact

Betsy Wonderly
Daktari Diagnostics
media@daktaridx.com
+1 (617) 336-3299

Photo - http://photos.prnewswire.com/prnh/20140325/NE90169-a
Logo - http://photos.prnewswire.com/prnh/20140325/NE90169LOGO-b


'/>"/>
SOURCE Daktari Diagnostics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. New Drug Application For Naloxegol Accepted By United States Food And Drug Administration
2. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
3. New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA
4. Actavis NDA for Progestin-Only Patch Accepted for Filing by FDA
5. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
6. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
7. CardioChek Test System Accepted by HEART UK for Use in Nationwide Program
8. Beckman Coulter to Acquire Siemens Healthcare Diagnostics Clinical Microbiology Business
9. Decline in Prescription Drug Misuse More than Twice as High in States with Broad Drug Abuse Prevention Programs, New Quest Diagnostics Health Trends Study Finds
10. Diagnostics Market in Transition--Amid Regulatory Uncertainty and Intensifying Competition
11. Diomics Announces Issuance Of U.S. Patents For Novel Biologic Sample DNA Collection Materials For Use In Forensics And Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... ... company, today announced the launch of DonorBridge, its process and engagement analytics ... of software innovation and industry expertise with predictive analytics to help nonprofits ...
(Date:4/29/2017)... ... ... More than half of Americans suffering from noise-induced hearing loss do not ... causes hearing loss? May 1 marks the beginning of Better Hearing & Speech Month—a ... as schedule a hearing evaluation for anyone with concerns about his/her hearing. , Approximately ...
(Date:4/28/2017)... ... April 28, 2017 , ... It's not always common knowledge ... of illnesses that are unclear as to whether or not they are contagious, and ... one of these illnesses. So, FindaTopDoc took a look into the matter. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced ... test throughout the Northeast U.S. , GlycoMark is the only clinically available ... test provides a clinically proven one- to two-week measure of hyperglycemic excursions, often ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
Breaking Medicine News(10 mins):